Zacks Investment Research upgraded shares of Celcuity (NASDAQ:CELC) from a sell rating to a hold rating in a research note published on Wednesday, Zacks.com reports.

According to Zacks, “Celcuity Inc. is a cellular analysis company. It engaged in discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The company’s proprietary CELx diagnostic platform uses a patient’s living tumor cells to identify the specific abnormal cellular activity driving a patient’s cancer and the targeted therapy. Celcuity Inc. is based in Minneapolis, United States. “

Separately, ValuEngine upgraded shares of Celcuity from a hold rating to a buy rating in a research note on Wednesday, October 2nd.

NASDAQ CELC traded down $0.12 during trading on Wednesday, reaching $10.57. The company’s stock had a trading volume of 16,200 shares, compared to its average volume of 7,864. The company has a debt-to-equity ratio of 0.01, a quick ratio of 22.60 and a current ratio of 22.60. The firm has a market cap of $133.59 million, a price-to-earnings ratio of -14.49 and a beta of 0.65. Celcuity has a twelve month low of $9.50 and a twelve month high of $28.00. The business’s fifty day moving average price is $15.30 and its 200-day moving average price is $19.30.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.02. As a group, sell-side analysts forecast that Celcuity will post -0.74 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. River & Mercantile Asset Management LLP acquired a new position in Celcuity in the second quarter valued at $318,000. Vanguard Group Inc. boosted its holdings in shares of Celcuity by 0.4% in the second quarter. Vanguard Group Inc. now owns 261,586 shares of the company’s stock valued at $6,540,000 after acquiring an additional 1,104 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of Celcuity by 5.2% in the second quarter. BlackRock Inc. now owns 311,023 shares of the company’s stock valued at $7,775,000 after acquiring an additional 15,395 shares in the last quarter. Captrust Financial Advisors boosted its holdings in shares of Celcuity by 300.0% in the second quarter. Captrust Financial Advisors now owns 3,000 shares of the company’s stock valued at $75,000 after acquiring an additional 2,250 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Celcuity by 1.5% in the second quarter. Northern Trust Corp now owns 64,763 shares of the company’s stock valued at $1,619,000 after acquiring an additional 958 shares in the last quarter. Institutional investors own 22.45% of the company’s stock.

About Celcuity

Celcuity Inc, a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the clinical outcomes of cancer patients treated with targeted therapies in the United States. The company's CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it.

Featured Story: Which market index is the best?

Get a free copy of the Zacks research report on Celcuity (CELC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.